AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Triglav Skladi D.O.O.

Key Points

• Triglav Skladi D.O.O. increased its stake in AstraZeneca by 7.6%, now owning 90,136 shares valued at approximately $6.6 million.
• AstraZeneca's recent earnings report showed a 16.1% year-over-year increase in revenue, reaching $14.46 billion, while earnings per share matched analysts' expectations at $1.09.
• Analysts have a current average rating of "Moderate Buy" for AstraZeneca, with a target price of $86.00, reflecting potential growth for the stock.

Triglav Skladi D.O.O. raised its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 7.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,136 shares of the company's stock after acquiring an additional 6,394 shares during the quarter. Triglav Skladi D.O.O.'s holdings in AstraZeneca were worth $6,624,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Dynamic Advisor Solutions LLC raised its holdings in shares of AstraZeneca by 58.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company's stock valued at $960,000 after purchasing an additional 4,811 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of AstraZeneca by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 498,831 shares of the company's stock worth $32,683,000 after acquiring an additional 5,384 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of AstraZeneca by 13.1% during the 1st quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company's stock worth $442,000 after acquiring an additional 706 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of AstraZeneca by 1.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 311,600 shares of the company's stock worth $22,903,000 after acquiring an additional 5,557 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its position in shares of AstraZeneca by 74.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 36,300 shares of the company's stock worth $2,378,000 after acquiring an additional 15,499 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of research analyst reports. BNP Paribas initiated coverage on AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target for the company. Berenberg Bank set a $97.00 price target on AstraZeneca in a report on Wednesday, July 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $86.00.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $75.34 on Wednesday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The stock has a 50 day moving average of $71.97 and a two-hundred day moving average of $71.73. The stock has a market cap of $233.65 billion, a P/E ratio of 28.32, a P/E/G ratio of 1.36 and a beta of 0.36.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting analysts' consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%. The company had revenue of $14.46 billion during the quarter, compared to analysts' expectations of $14.08 billion. During the same quarter in the previous year, the business earned $1.24 earnings per share. The firm's revenue for the quarter was up 16.1% on a year-over-year basis. On average, research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Monday, September 8th. Shareholders of record on Friday, August 8th will be paid a $0.505 dividend. The ex-dividend date is Friday, August 8th. This represents a yield of 200.0%. AstraZeneca's payout ratio is currently 37.97%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.